

David Gonzalez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7458778/publications.pdf>

Version: 2024-02-01

40
papers

1,646
citations

279487

23
h-index

301761

39
g-index

40
all docs

40
docs citations

40
times ranked

3739
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. <i>Leukemia</i> , 2019, 33, 2241-2253.	3.3	177
2	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet</i> , The, 2016, 388, 1002-1011.	6.3	132
3	Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. <i>Blood</i> , 2013, 121, 3413-3419.	0.6	128
4	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. <i>Blood</i> , 2003, 102, 2994-3002.	0.6	101
5	Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. <i>British Journal of Cancer</i> , 2017, 117, 876-883.	2.9	98
6	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. <i>Seminars in Oncology</i> , 2017, 44, 187-197.	0.8	76
7	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020, 26, 608-622.	3.2	71
8	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. <i>Leukemia</i> , 2019, 33, 2254-2265.	3.3	70
9	Next-generation sequencing: a change of paradigm in molecular diagnostic validation. <i>Journal of Pathology</i> , 2014, 234, 5-10.	2.1	68
10	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. <i>Journal of Immunology</i> , 2017, 198, 3765-3774.	0.4	61
11	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. <i>British Journal of Cancer</i> , 2017, 116, 669-678.	2.9	48
12	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	46
13	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019, 121, 224-235.	1.3	44
14	Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020, 11, 2189.	5.8	43
15	A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1029-1039.	0.5	38
16	Detection of EGFR Variants in Plasma. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 483-494.	1.2	37
17	Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. <i>Haematologica</i> , 2017, 102, e57-e60.	1.7	35
18	Analysis of <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> and <i>TP53</i> mutations in a large prospective series of locally advanced rectal cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 94-102.	2.3	34

#	ARTICLE	IF	CITATIONS
19	Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. <i>Nature Communications</i> , 2016, 7, 13840.	5.8	32
20	Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. <i>BMC Cancer</i> , 2019, 19, 582.	1.1	32
21	Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 631-640.	1.4	28
22	Disease-associated and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations. <i>Journal of Pathology</i> , 2019, 247, 416-421.	2.1	25
23	Angiomatoid fibrous histiocytoma: comparison of fluorescence in situ hybridization and reverse transcription polymerase chain reaction as adjunct diagnostic modalities. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 137-142.	0.6	24
24	An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice. <i>Human Mutation</i> , 2018, 39, 394-405.	1.1	24
25	The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories. <i>HemaSphere</i> , 2021, 5, e568.	1.2	22
26	A novel next generation sequencing approach to improve sarcoma diagnosis. <i>Modern Pathology</i> , 2020, 33, 1350-1359.	2.9	20
27	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 311-325.	1.3	19
28	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 299-302.	1.5	16
29	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. <i>Oncotarget</i> , 2017, 8, 112036-112050.	0.8	16
30	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016, 37, 852-857.	1.3	15
31	HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee. <i>Journal of Clinical Pathology</i> , 2018, 71, 388-394.	1.0	14
32	The impact of <i>SAMHD1</i> expression and mutation status in mantle cell lymphoma: An analysis of the <i>MCL</i> Younger and Elderly trial. <i>International Journal of Cancer</i> , 2021, 148, 150-160.	2.3	10
33	Relevance of TP53 for CLL diagnostics. <i>Journal of Clinical Pathology</i> , 2019, 72, 343-346.	1.0	10
34	Ancillary molecular analysis in the diagnosis of soft tissue tumours: reassessment of its utility at a specialist centre. <i>Journal of Clinical Pathology</i> , 2016, 69, 505-510.	1.0	9
35	Evaluation of the optimal provision of formalin-fixed, paraffin-embedded material for reverse transcription-PCR in soft-tissue tumour diagnosis. <i>Journal of Clinical Pathology</i> , 2017, 70, 20-24.	1.0	9
36	Detection of Structural Variants in Circulating Cell-Free DNA from Sarcoma Patients Using Next Generation Sequencing. <i>Cancers</i> , 2020, 12, 3627.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Gastrointestinal Stromal Tumor With Multiple Primary Tyrosine Kinase Mutationsâ€™ Clinicopathologic and Molecular Characterization. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 461-465.	0.6	4
38	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. <i>Blood Advances</i> , 2021, 5, 3188-3198.	2.5	2
39	NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods. <i>Molecular Biology and Evolution</i> , 2019, 36, 2883-2889.	3.5	1
40	Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study. <i>Blood</i> , 2020, 136, 12-13.	0.6	0